K. Wieland et al., INVOLVEMENT OF ASN-293 IN STEREOSPECIFIC AGONIST RECOGNITION AND IN ACTIVATION OF THE BETA(2)-ADRENERGIC RECEPTOR, Proceedings of the National Academy of Sciences of the United Statesof America, 93(17), 1996, pp. 9276-9281
To investigate the molecular mechanism for stereospecific binding of a
gonists to beta(2)-adrenergic receptors rye used receptor models to id
entify potential binding sites for the beta-OH-group of the ligand, wh
ich defines the chiral center. Ser-165, located in transmembrane helix
IV, and Asn-293, situated in the upper half of transmembrane helix VI
, were identified as potential binding sites. Mutation of Ser-165 to A
la did not change the binding of either isoproterenol isomer as reveal
ed after transient expression in human embryonic kidney (HEK)-293 cell
s, In contrast, a receptor mutant in which Asn-293 was replaced by Leu
showed substantial loss of stereospecific isoproterenol binding. Aden
ylyl cyclase stimulation by this mutant after stable expression in CHO
cells confirmed the substantial loss of stereospecificity for isoprot
erenol, In a series of agonists the loss of affinity in the Leu-293 mu
tant receptor was strongly correlated with the intrinsic activity of t
he compounds, Full agonists showed a 10-30-fold affinity loss, whereas
partial agonists had almost the same affinity for bath receptors, Ste
reospecific recognition of antagonists was unaltered in the Leu-293 mu
tant receptor, These data indicate a relationship between stereospecif
icity and intrinsic activity of agonists and suggest that Asn-293 is i
mportant for both properties of the agonist-receptor interaction.